Hexavest’s Jazz Pharmaceuticals JAZZ Stock Holding History

Hexavest’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-78	Closed	-$8K	–	434
2020 Q1	$8K	Hold	78	–	–	﹤0.01%	406
2019 Q4	$12K	Hold	78	–	–	﹤0.01%	401
2019 Q3	$10K	Hold	78	–	–	﹤0.01%	472
2019 Q2	$11K	Buy	+78	New	+$10.5K	﹤0.01%	466

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Hexavest's JAZZ Position: Q2 2020 in Review

Hexavest sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2020, closing a stake of 78 shares — an estimated $8K sold.

Hexavest first reported a position in JAZZ in Q2 2019 and held it in 4 quarters. The position peaked at $12K in Q4 2019. 384 funds tracked by Wall St. Rank hold JAZZ as of Q2 2020.

Hexavest reported no remaining Jazz Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Hexavest sold 78 Jazz Pharmaceuticals shares in Q2 2020, an estimated $8K.
Hexavest first reported a position in Jazz Pharmaceuticals in Q2 2019 and held it in 4 quarters.
Hexavest's Jazz Pharmaceuticals position peaked at $12K in Q4 2019.
384 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2020.

Based on Hexavest's 13F filing for Q2 2020, filed 10 Jul 2020.